TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03719027

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Study population
Description: Dyspnea assessment (NYHA functional class) EKG Echocardiography
Study: NCT02451761

Intervention type: BIOLOGICAL
Intervention: Blood sampling
Study: NCT01819870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dilatrend SR capsule 32mg
Description: * 1 capsule, oral, once daily, 7days~* over the period I\&II(crossover)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dilatrend IR tablet 25mg
Description: * 1 tablet, oral, once daily, 7days~* over the period I\&II(crossover)
Study: NCT01521377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Moxifloxacin
Description: Single dose placebo oral tablet Moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Moxifloxacin
Description: Single dose placebo oral tablet Moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Moxifloxacin
Description: Single dose placebo oral tablet Moxifloxacin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Moxifloxacin
Description: Single dose placebo oral tablet Moxifloxacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Single oral dose tablet Moxifloxacin (400mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719/Vilanterol 125/25mcg
Description: Single inhalation from GSK573719/Vilanterol 125/25mcg DPI once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719
Description: Single inhalation from GSK573719 500mcg DPI once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719/Vilanterol 500/100mcg
Description: Single inhalation from GSK573719/Vilanterol 500/100mcg DPI once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo DPI
Description: Single Inhalation from matching Placebo DPI once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo DPI
Description: Single Inhalation from matching Placebo DPI once daily
Study: NCT03424603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STRO-001
Description: intravenous antibody drug conjugate
Study: NCT01201226

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Removal of half an ovary
Description: Removal of half an ovary
Study: NCT01248637

Intervention type: DRUG
Intervention: Pimonidazole hydrochloride
Description: Pimonidazole is a 2-nitroimidazole that is selectively reduced and covalently binds to intracellular macromolecules in areas of hypoxia (by definition, p02 \<= 10mm Hg) within normal and tumour tissue. Pimonidazole adducts can then be detected by immunolabelling techniques (microscopy, ELISA, flow cytometry etc). In this study, pimonidazole will be administered orally as a one time dose of 0.5gm/m2 24hrs prior to surgery. Since the drug has a half-life of approximately 5 hrs, this time-frame ensures low circulating levels at the time of surgery and therefore reduces the confounding effects of surgical hypoxia on tumour analysis.
Study: NCT02253784

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Study: NCT01630889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Oral capsule
Study: NCT00486382

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Leish-111f + MPL-SE Adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Leish-111f + MPL-SE Adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Leish-111f + MPL-SE Adjuvant
Study: NCT03217214

Intervention type: DIAGNOSTIC_TEST
Intervention: Thermography
Description: Passive thermography for Phase I subjects and Active Thermography for Phase II subjects

Intervention type: DIAGNOSTIC_TEST
Intervention: Thermography
Description: Passive thermography for Phase I subjects and Active Thermography for Phase II subjects
Study: NCT02974842

Intervention type: DEVICE
Intervention: MAKO 7
Description: Hysteroscopic cell sampling
Study: NCT03968848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib
Description: A 50-mg single oral dose of acalabrutinib will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib
Description: A 50-mg single oral dose of acalabrutinib will be administered.
Study: NCT03262467

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aneurysmorrhaphy with or without external porous prosthesis (Provena©, BBraun)
Description: In patients with aneurysm of native vascular access indicated for surgical treatment, aneurysmorrhaphy with or without external porous prosthesis (Provena©, BBraun) wil be performed.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Aneurysmorrhaphy with or without external porous prosthesis (Provena©, BBraun)
Description: In patients with aneurysm of native vascular access indicated for surgical treatment, aneurysmorrhaphy with or without external porous prosthesis (Provena©, BBraun) wil be performed.
Study: NCT00848224

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: systems-based and pharmacist-mediated program
Description: Patients in the SI were seen by a study pharmacists prior to discharge to establish a relationship with the patient, explain the pharmacist's role in the study, provide education about all discharge medications and a medication card listing all medications and their manner of use, and set the framework for the follow-up telephone calls. Patients received pharmacist-delivered adherence counseling telephone contacts that took place at two weeks following discharge, and at months 1, 3, 6, and 9 oriented towards assisting patients to remain adherent to prescribed lipid-lowering and other medications, and also towards ensuring that all patients were either documented to be at the LDL-C goal, or were assisted to reach the goal by facilitating the scheduling of repeat lipid measurement as needed and providing information, guidelines and prompts to the patient's physician or nurse practitioner.
Study: NCT01854424

Intervention type: OTHER
Intervention: Bronchoalveolar lavage (BAL) before day 2 , between days 5-7 and days 10-14 of evolution.
Description: All the samples will be obtained during current care in the first week of evolution, and the last set of samples (BAL and blood sample between day 10-14) only in patients still under ventilation at this time point.
Study: NCT01265303

Intervention type: DEVICE
Group type: OTHER
Intervention: Prolonged telemetric Full Disclosure ECG recording.
Description: Continuous Full Disclosure Telemetric ECG monitoring lasting 14 days

Intervention type: DEVICE
Group type: OTHER
Intervention: Prolonged telemetric Full Disclosure ECG recording.
Description: Continuous Full Disclosure Telemetric ECG monitoring lasting 14 days

Intervention type: DEVICE
Group type: OTHER
Intervention: Prolonged telemetric Full Disclosure ECG recording.
Description: Continuous Full Disclosure Telemetric ECG monitoring lasting 14 days
Study: NCT01509911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-118
Description: TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Monthly cycles of 3 weekly treatments a month and one week off of treatment
Study: NCT02982291

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Williams flexion protocol
Description: The Williams flexion protocol group will participate in 15 treatment sessions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focused spinal stenosis rehabilitation
Description: The focused spinal stenosis rehabilitation group will participate in 5 treatment sessions.
Study: NCT00946920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: The degarelix doses were administered by subcutaneous (s.c.) injections into the abdominal wall. A starting dose of 240 mg degarelix was administered on Day 0. One month later a maintenance dose of 480 mg was administered. This was repeated after 4, 7, and 10 months (ie a total of 5 administrations).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin acetate
Description: The goserelin doses were administered by subcutaneous (s.c.) implants into the abdominal wall. An initial dose of 3.6 mg goserelin was administered on Day 0. One month later a subsequent dose of 10.8 mg was administered and this was repeated after 4, 7, and 10 months (ie a total of 5 implants).
Study: NCT04392895

Intervention type: PROCEDURE
Intervention: Para Aortic Lymphadenectomy (PAL) by laparoscopy
Description: Para Aortic Lymphadenectomy (PAL) by laparoscopy
Study: NCT04097340

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Attentional Bias Retraining (ABR)
Description: Participants randomized to this intervention will receive 2 weeks of ABR for opioids delivered via a mobile device.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control Training
Description: Participants randomized to this intervention will receive 2 weeks of training without ABR, delivered via a mobile device.
Study: NCT02461160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-915 suspension
Description: TAK-915 oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-915 suspension
Description: TAK-915 oral suspension
Study: NCT02122224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fiber breakfast
Description: Breakfast will contain 10-11g fiber.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fiber breakfast
Description: Breakfast will contain 10-11g fiber.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fiber breakfast
Description: Breakfast will contain 10-11g fiber.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fiber breakfast
Description: Breakfast will contain 10-11g fiber.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein Breakfast
Description: Breakfast will contain 19-20g of protein.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein Breakfast
Description: Breakfast will contain 19-20g of protein.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein Breakfast
Description: Breakfast will contain 19-20g of protein.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein Breakfast
Description: Breakfast will contain 19-20g of protein.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein/High Fiber Breakfast
Description: Breakfast will include 19-22g of protein and 10-12g of fiber.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein/High Fiber Breakfast
Description: Breakfast will include 19-22g of protein and 10-12g of fiber.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein/High Fiber Breakfast
Description: Breakfast will include 19-22g of protein and 10-12g of fiber.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein/High Fiber Breakfast
Description: Breakfast will include 19-22g of protein and 10-12g of fiber.
Study: NCT00486668

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: 60 mg/m2 IV every 21 days for cycles 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 60 mg/m2 IV every 21 days for cycles 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 60 mg/m2 IV every 21 days for cycles 1-4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 600 mg/m2 IV every 21 days for cycles 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 600 mg/m2 IV every 21 days for cycles 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 600 mg/m2 IV every 21 days for cycles 1-4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 80 mg/m2 IV on days 1, 8, and 15 every 28 days for cycles 5-8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 80 mg/m2 IV on days 1, 8, and 15 every 28 days for cycles 5-8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 80 mg/m2 IV on days 1, 8, and 15 every 28 days for cycles 5-8

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: First dose: 4 mg/kg IV, subsequent doses: 2 mg/kg IV weekly beginning on day 1 of the first paclitaxel cycle until 1-7 days before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: First dose: 4 mg/kg IV, subsequent doses: 2 mg/kg IV weekly beginning on day 1 of the first paclitaxel cycle until 1-7 days before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: Group 2: 1250 mg PO daily beginning on day 1 of the first paclitaxel cycle until 1 day before surgery. Group 3: 750 mg PO daily beginning on day 1 of the first paclitaxel cycle until 1 day before surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: Group 2: 1250 mg PO daily beginning on day 1 of the first paclitaxel cycle until 1 day before surgery. Group 3: 750 mg PO daily beginning on day 1 of the first paclitaxel cycle until 1 day before surgery.
Study: NCT03633812

Intervention type: OTHER
Intervention: Observational study, Beta blocker medication history
Description: Observational study, Beta blocker medication history
Study: NCT00637962

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV glycoprotein CN54gp140 (vaccine)
Description: vaginal immunisation with 100ug CN54gp140 antigen in gel on 9 occasions in one menstrual cycle

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Carbopol 974
Description: vaginal immunisation with Carbopol 974 P 0.924%; benzyl alcohol 1.09%; sodium hydroxide 0.176%; and purified water 97.81%. alone on 9 occasions in one menstrual cycle
Study: NCT03614299

Intervention type: OTHER
Intervention: Ecological symptom measurements using a webapp
Description: A webapp will be installed on the patients' smartphone, which will be used to collect everyday the symptoms of the patients (ESSPRI score)

Intervention type: DIAGNOSTIC_TEST
Intervention: Interferometry
Description: Evaluation of the mebomian function using the LipiView methodology
Study: NCT02053961

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep Transcranial Magnetic Stimulation
Description: 1Hz dTMS real treatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Transcranial Magnetic Stimulation
Description: 1Hz dTMS real treatment

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep Transcranial Magnetic Stimulation
Description: 1Hz dTMS SHAM treatment
Study: NCT00326443

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVD 909
Description: 5 X 10\^9 CFU of oral S. Typhi vaccine strain CVD 909 with buffer administered on Day 0.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Buffer placebo administered on Day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi Polysaccharide
Description: 25 micrograms (0.5 ml) of licensed purified Vi polysaccharide vaccine on Day 21.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vi Polysaccharide
Description: 25 micrograms (0.5 ml) of licensed purified Vi polysaccharide vaccine on Day 21.
Study: NCT00056030

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Study: NCT02514148

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic patient education
Description: Therapeutic patient education based on pain physiology from a biobehavioral perspective adding a training in coping strategies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic patient education
Description: Therapeutic patient education based on pain physiology from a biobehavioral perspective adding a training in coping strategies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic patient education
Description: Therapeutic patient education based on pain physiology from a biobehavioral perspective adding a training in coping strategies.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: Therapeutic exercise consist on stretch of cervical-scapular muscles ( Trapezius and angular of the scapula), Cranium-cervical flexor stabilization exercise, auto cervical tractions, shoulders rotation, low intensity exercise ( walking), craniocervical extension, cervical flexion and extension.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: Therapeutic exercise consist on stretch of cervical-scapular muscles ( Trapezius and angular of the scapula), Cranium-cervical flexor stabilization exercise, auto cervical tractions, shoulders rotation, low intensity exercise ( walking), craniocervical extension, cervical flexion and extension.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: Therapeutic exercise consist on stretch of cervical-scapular muscles ( Trapezius and angular of the scapula), Cranium-cervical flexor stabilization exercise, auto cervical tractions, shoulders rotation, low intensity exercise ( walking), craniocervical extension, cervical flexion and extension.

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: No intervention consist on measure the whole variables in chronic migraine patients to compare it with experimental interventions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Manual therapy consist on ; oscillatory traction , maintained craniocervical traction, upper cervical flexion mobilization, side glide roll, anterior-posterior upper cervical mobilization with wedge, lateral glide at the C1-C2 and C2-C3 levels, retraction technique, trigeminocervical neural mobilization , and upper cervical traction, followed by posterior-anterior glide at C4.
Study: NCT01850355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: Children with autism spectrum disorders will receive buspirone treatment for eight weeks. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards, subjects will be maintained on maximum achieved dose until the end of the trial (dose maintenance pahe). During the titration phase, total dose will be increased by 10mg at each visit and by 5mg on the 4th day after each visit.
Study: NCT03504631

Intervention type: OTHER
Intervention: No intervention
Description: no intervention
Study: NCT01105598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1002 or placebo
Description: ETC-1002 (ascending dose), daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1002 or placebo
Description: ETC-1002 (ascending dose), daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1002 or placebo
Description: ETC-1002 (ascending dose), daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1002 or placebo
Description: ETC-1002 (optimized dose), daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1002 or placebo
Description: ETC-1002 (20 mg), daily for 14 days
Study: NCT02572622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non -surgical spinal decompression therapy
Description: it is a kind of traction therapy, it has an special traction design which can provide intermittent traction as to herniation levels.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non -surgical spinal decompression therapy
Description: it is a kind of traction therapy, it has an special traction design which can provide intermittent traction as to herniation levels.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: deep friction massage,
Description: deep friction massage is a kind of massage targeting deep muscles for decreasing pain and increasing function

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: deep friction massage,
Description: deep friction massage is a kind of massage targeting deep muscles for decreasing pain and increasing function

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrotherapy
Description: electrotherapy is consist of hot pack, ultrasound and TENS. electrotherapy agents were help decreasing pain, increasing metabolism of tissues.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrotherapy
Description: electrotherapy is consist of hot pack, ultrasound and TENS. electrotherapy agents were help decreasing pain, increasing metabolism of tissues.
Study: NCT00056030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study: NCT02572622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: special lumbar stabilization exercises were applied in advanced protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: special lumbar stabilization exercises were applied in advanced protocol.
Study: NCT03202264

Intervention type: OTHER
Intervention: TAPER
Description: The intervention is medication reduction. This arm is comprised of:~* Medication reconciliation~* Identification of patient priorities for care~* Identification of medications that are potentially appropriate for discontinuation/dose reduction~* Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce~* Identification of medications for trial of discontinuation/dose reduction (shared decision making)~* Pause of medication and clinical monitoring
Study: NCT03025061

Intervention type: OTHER
Intervention: Assessment of E-nose measurements
Description: Breath sampling through E-nose pneumopipe

Intervention type: OTHER
Intervention: Assessment of E-nose measurements
Description: Breath sampling through E-nose pneumopipe
Study: NCT03929848

Intervention type: PROCEDURE
Intervention: Cuff pressure
Description: observe and record the required cuff pressure to prevent gas leakage during mechanical ventilation for laryngomicrosurgery

Intervention type: PROCEDURE
Intervention: Cuff pressure
Description: observe and record the required cuff pressure to prevent gas leakage during mechanical ventilation for laryngomicrosurgery